Tip:
Highlight text to annotate it
X
>>>Dr. Margileth: There was a trial mainly conducted in Canada called the MA.17 trial
where they took postmenopausal patients who had completed five years of tamoxifen and
randomized those patients to take no further therapy or five years of an aromatase inhibitor.
What they found was that at about year eight or year nine, there was a benefit to patients
that took the additional aromatase inhibitor. This benefit was about 6% and the majority
of that benefit was in patients who had lymph node-positive disease.
This trial has become a little outdated in that the most current approach to post menopausal
patients would be to begin not with tamoxifen but with an aromatase inhibitor which brings
up the issue of 10 years versus 5 years of an aromatase inhibitor.
But over the past year or two there have been a number of postmenopausal patients who are
coming off five years of tamoxifen for which that question is appropriate. My general approach
has been in the patients with low grade or lymph node-negative breast cancer to not proceed
with five years of an aromatase inhibitor, but patients with large tumors or poor prognostic
factors or patients with lymph node-positive disease to consider adding five years of an
aromatase inhibitor to the five years of tamoxifen. *****
Hi, I am Dr. Jay Harness and I want to share with you an important information that I believe
that every newly diagnosed patient with breast cancer needs to know.
Susan Denver: “I am a breast cancer survivor.”
Katherine Stockton: “I am a breast cancer survivor.”
Coree: “I am a breast cancer survivor…”
Susan Denver: “…and I want every woman to know…”
Katherine Stockton: “…about personalized breast cancer treatment…”
Susan Denver: “…and the Genomic Test.”
Coree: “A test that helps guide a woman and her doctor…”
Katherine Stockton: “…to the best treatment options for her.”
Susan Denver: “Pass it on!”